Posts Tagged ‘XELJANZ-tofacitinib-JAK’

  • New Way to Report Response in RA Clinical Trials?

    Untangling a possible replacement for the “familiar” ACR 20 describing treatment response in clinical trials for Rheumatoid Arthritis Special thanks to Jay Sprinkel for assistance with this post. Although he may be more known for the humor he provides to our Facebook group, Jay is a retired marine biologist who specializes in statistics. He is […]

  • Tofacitinib / CP-690550 aka Tasocitinib Succeeds in Pfizer’s 2nd Phase 3 Trial

    A new name and new milestone for tofacitinib Pfizer announced Friday that CP-690550 tofacitinib (formerly tasocitinib) met its goals in its second phase three clinical trial for moderate to severe Rheumatoid Arthritis. Tofacitinib is a JAK 3 inhibitor, an oral treatment for RA with a different approach than current Biologic RA treatments. According to Pfizer, […]

  • Rheumatoid Arthritis Drug Trials for Tasocitinib aka CP-690550

    Phase 3 Rheumatoid Arthritis drug trials mean more widespread testing of Tasocitinib aka CP-690550 Last night, I learned some exciting news about a new kind of Rheumatoid Arthritis drug in development called Tasocitinib. Tasocitinib is administered in a pill form. However, it is being compared to Biologics which are administered intravenously or injected. Tasocitinib, also […]

Would You Like Free Email Updates?
Stay in touch with RA Warrior.
We respect your privacy. Your email address will never be shared.